BrainsWay Ltd. (NASDAQ: BWAY) Stock Competitors & Peer Comparison
See BWAY's competitors and their performance on the NASDAQ and across the wider stock market.
Peer Comparison Table: Medical - Devices Industry
Detailed financial metrics including price, market cap, P/E ratio, and more for BWAY and its NASDAQ peers.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| BWAY | $14.98 | -2.22% | 587.6M | 38.06 | $0.39 | N/A |
| ABT | $109.72 | +1.01% | 189.9B | 21.06 | $5.21 | +2.26% |
| BSX-PA | $122.18 | +2.37% | 175.4B | 230.53 | $0.53 | N/A |
| SYK | $348.15 | +0.68% | 133.4B | 25.99 | $13.39 | +1.00% |
| MDT | $90.68 | +1.42% | 116B | 16.39 | $5.53 | +3.15% |
| BSX | $51.19 | +1.45% | 76.1B | 16.51 | $3.10 | N/A |
| EW | $93.66 | +1.77% | 53.9B | 34.69 | $2.70 | N/A |
| DXCM | $89.53 | +2.14% | 33.8B | 38.42 | $2.33 | N/A |
| RMD | $224.84 | +2.18% | 32.6B | 20.87 | $10.77 | +1.07% |
| PHG | $27.05 | +0.41% | 26.4B | 15.46 | $1.75 | +3.65% |
Stock Comparison
Abbott Laboratories (NYSE: ABT)
BWAY vs ABT Comparison August 2026
BrainsWay Ltd. (NASDAQ: BWAY) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BWAY stands at 587.6M. In comparison, ABT has a market cap of 189.9B. Regarding current trading prices, BWAY is priced at $14.98 on the NASDAQ, while ABT trades at $109.72.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BWAY currently has a P/E ratio of 38.06, whereas ABT's P/E ratio is 21.06. In terms of profitability, BWAY's ROE is +0.12%, compared to ABT's ROE of +0.11%. Regarding short-term risk, BWAY is more volatile compared to ABT. This indicates higher risk in terms of short-term price fluctuations for BWAY.Check ABT's competition here
Boston Scientific Corporation (NYSE: BSX-PA)
BWAY vs BSX-PA Comparison August 2026
BrainsWay Ltd. (NASDAQ: BWAY) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BWAY stands at 587.6M. In comparison, BSX-PA has a market cap of 175.4B. Regarding current trading prices, BWAY is priced at $14.98 on the NASDAQ, while BSX-PA trades at $122.18.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BWAY currently has a P/E ratio of 38.06, whereas BSX-PA's P/E ratio is 230.53. In terms of profitability, BWAY's ROE is +0.12%, compared to BSX-PA's ROE of +0.15%. Regarding short-term risk, BWAY is less volatile compared to BSX-PA. This indicates lower risk in terms of short-term price fluctuations for BWAY.Check BSX-PA's competition here
Stryker Corporation (NYSE: SYK)
BWAY vs SYK Comparison August 2026
BrainsWay Ltd. (NASDAQ: BWAY) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BWAY stands at 587.6M. In comparison, SYK has a market cap of 133.4B. Regarding current trading prices, BWAY is priced at $14.98 on the NASDAQ, while SYK trades at $348.15.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BWAY currently has a P/E ratio of 38.06, whereas SYK's P/E ratio is 25.99. In terms of profitability, BWAY's ROE is +0.12%, compared to SYK's ROE of +0.16%. Regarding short-term risk, BWAY is more volatile compared to SYK. This indicates higher risk in terms of short-term price fluctuations for BWAY.Check SYK's competition here
Medtronic plc (NYSE: MDT)
BWAY vs MDT Comparison August 2026
BrainsWay Ltd. (NASDAQ: BWAY) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BWAY stands at 587.6M. In comparison, MDT has a market cap of 116B. Regarding current trading prices, BWAY is priced at $14.98 on the NASDAQ, while MDT trades at $90.68.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BWAY currently has a P/E ratio of 38.06, whereas MDT's P/E ratio is 16.39. In terms of profitability, BWAY's ROE is +0.12%, compared to MDT's ROE of +0.10%. Regarding short-term risk, BWAY is more volatile compared to MDT. This indicates higher risk in terms of short-term price fluctuations for BWAY.Check MDT's competition here
Boston Scientific Corporation (NYSE: BSX)
BWAY vs BSX Comparison August 2026
BrainsWay Ltd. (NASDAQ: BWAY) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BWAY stands at 587.6M. In comparison, BSX has a market cap of 76.1B. Regarding current trading prices, BWAY is priced at $14.98 on the NASDAQ, while BSX trades at $51.19.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BWAY currently has a P/E ratio of 38.06, whereas BSX's P/E ratio is 16.51. In terms of profitability, BWAY's ROE is +0.12%, compared to BSX's ROE of +0.15%. Regarding short-term risk, BWAY is more volatile compared to BSX. This indicates higher risk in terms of short-term price fluctuations for BWAY.Check BSX's competition here
Edwards Lifesciences Corporation (NYSE: EW)
BWAY vs EW Comparison August 2026
BrainsWay Ltd. (NASDAQ: BWAY) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BWAY stands at 587.6M. In comparison, EW has a market cap of 53.9B. Regarding current trading prices, BWAY is priced at $14.98 on the NASDAQ, while EW trades at $93.66.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BWAY currently has a P/E ratio of 38.06, whereas EW's P/E ratio is 34.69. In terms of profitability, BWAY's ROE is +0.12%, compared to EW's ROE of +0.10%. Regarding short-term risk, BWAY is more volatile compared to EW. This indicates higher risk in terms of short-term price fluctuations for BWAY.Check EW's competition here
DexCom, Inc. (NASDAQ: DXCM)
BWAY vs DXCM Comparison August 2026
BrainsWay Ltd. (NASDAQ: BWAY) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BWAY stands at 587.6M. In comparison, DXCM has a market cap of 33.8B. Regarding current trading prices, BWAY is priced at $14.98 on the NASDAQ, while DXCM trades at $89.53.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BWAY currently has a P/E ratio of 38.06, whereas DXCM's P/E ratio is 38.42. In terms of profitability, BWAY's ROE is +0.12%, compared to DXCM's ROE of +0.36%. Regarding short-term risk, BWAY is less volatile compared to DXCM. This indicates lower risk in terms of short-term price fluctuations for BWAY.Check DXCM's competition here
ResMed Inc. (NYSE: RMD)
BWAY vs RMD Comparison August 2026
BrainsWay Ltd. (NASDAQ: BWAY) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BWAY stands at 587.6M. In comparison, RMD has a market cap of 32.6B. Regarding current trading prices, BWAY is priced at $14.98 on the NASDAQ, while RMD trades at $224.84.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BWAY currently has a P/E ratio of 38.06, whereas RMD's P/E ratio is 20.87. In terms of profitability, BWAY's ROE is +0.12%, compared to RMD's ROE of +0.24%. Regarding short-term risk, BWAY is less volatile compared to RMD. This indicates lower risk in terms of short-term price fluctuations for BWAY.Check RMD's competition here
Koninklijke Philips N.V. (NYSE: PHG)
BWAY vs PHG Comparison August 2026
BrainsWay Ltd. (NASDAQ: BWAY) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BWAY stands at 587.6M. In comparison, PHG has a market cap of 26.4B. Regarding current trading prices, BWAY is priced at $14.98 on the NASDAQ, while PHG trades at $27.05.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BWAY currently has a P/E ratio of 38.06, whereas PHG's P/E ratio is 15.46. In terms of profitability, BWAY's ROE is +0.12%, compared to PHG's ROE of +0.10%. Regarding short-term risk, BWAY is more volatile compared to PHG. This indicates higher risk in terms of short-term price fluctuations for BWAY.Check PHG's competition here
Zimmer Biomet Holdings, Inc. (NYSE: ZBH)
BWAY vs ZBH Comparison August 2026
BrainsWay Ltd. (NASDAQ: BWAY) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BWAY stands at 587.6M. In comparison, ZBH has a market cap of 18.8B. Regarding current trading prices, BWAY is priced at $14.98 on the NASDAQ, while ZBH trades at $97.23.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BWAY currently has a P/E ratio of 38.06, whereas ZBH's P/E ratio is 11.46. In terms of profitability, BWAY's ROE is +0.12%, compared to ZBH's ROE of +0.06%. Regarding short-term risk, BWAY is more volatile compared to ZBH. This indicates higher risk in terms of short-term price fluctuations for BWAY.Check ZBH's competition here
Abiomed, Inc. (NASDAQ: ABMD)
BWAY vs ABMD Comparison August 2026
BrainsWay Ltd. (NASDAQ: BWAY) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BWAY stands at 587.6M. In comparison, ABMD has a market cap of 17.2B. Regarding current trading prices, BWAY is priced at $14.98 on the NASDAQ, while ABMD trades at $381.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BWAY currently has a P/E ratio of 38.06, whereas ABMD's P/E ratio is 65.36. In terms of profitability, BWAY's ROE is +0.12%, compared to ABMD's ROE of +0.10%. Regarding short-term risk, BWAY is more volatile compared to ABMD. This indicates higher risk in terms of short-term price fluctuations for BWAY.Check ABMD's competition here
Penumbra, Inc. (NYSE: PEN)
BWAY vs PEN Comparison August 2026
BrainsWay Ltd. (NASDAQ: BWAY) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BWAY stands at 587.6M. In comparison, PEN has a market cap of 12.9B. Regarding current trading prices, BWAY is priced at $14.98 on the NASDAQ, while PEN trades at $326.28.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BWAY currently has a P/E ratio of 38.06, whereas PEN's P/E ratio is 85.23. In terms of profitability, BWAY's ROE is +0.12%, compared to PEN's ROE of +0.11%. Regarding short-term risk, BWAY is more volatile compared to PEN. This indicates higher risk in terms of short-term price fluctuations for BWAY.Check PEN's competition here
Smith & Nephew plc (NYSE: SNN)
BWAY vs SNN Comparison August 2026
BrainsWay Ltd. (NASDAQ: BWAY) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BWAY stands at 587.6M. In comparison, SNN has a market cap of 12.6B. Regarding current trading prices, BWAY is priced at $14.98 on the NASDAQ, while SNN trades at $30.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BWAY currently has a P/E ratio of 38.06, whereas SNN's P/E ratio is 14.12. In terms of profitability, BWAY's ROE is +0.12%, compared to SNN's ROE of +0.12%. Regarding short-term risk, BWAY is more volatile compared to SNN. This indicates higher risk in terms of short-term price fluctuations for BWAY.Check SNN's competition here
ShockWave Medical, Inc. (NASDAQ: SWAV)
BWAY vs SWAV Comparison August 2026
BrainsWay Ltd. (NASDAQ: BWAY) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BWAY stands at 587.6M. In comparison, SWAV has a market cap of 12.6B. Regarding current trading prices, BWAY is priced at $14.98 on the NASDAQ, while SWAV trades at $334.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BWAY currently has a P/E ratio of 38.06, whereas SWAV's P/E ratio is 78.76. In terms of profitability, BWAY's ROE is +0.12%, compared to SWAV's ROE of +0.25%. Regarding short-term risk, BWAY is more volatile compared to SWAV. This indicates higher risk in terms of short-term price fluctuations for BWAY.Check SWAV's competition here
Align Technology, Inc. (NASDAQ: ALGN)
BWAY vs ALGN Comparison August 2026
BrainsWay Ltd. (NASDAQ: BWAY) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BWAY stands at 587.6M. In comparison, ALGN has a market cap of 12.4B. Regarding current trading prices, BWAY is priced at $14.98 on the NASDAQ, while ALGN trades at $172.96.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BWAY currently has a P/E ratio of 38.06, whereas ALGN's P/E ratio is 15.77. In terms of profitability, BWAY's ROE is +0.12%, compared to ALGN's ROE of +0.14%. Regarding short-term risk, BWAY is less volatile compared to ALGN. This indicates lower risk in terms of short-term price fluctuations for BWAY.Check ALGN's competition here
Globus Medical, Inc. (NYSE: GMED)
BWAY vs GMED Comparison August 2026
BrainsWay Ltd. (NASDAQ: BWAY) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BWAY stands at 587.6M. In comparison, GMED has a market cap of 11.5B. Regarding current trading prices, BWAY is priced at $14.98 on the NASDAQ, while GMED trades at $85.15.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BWAY currently has a P/E ratio of 38.06, whereas GMED's P/E ratio is 19.17. In terms of profitability, BWAY's ROE is +0.12%, compared to GMED's ROE of +0.12%. Regarding short-term risk, BWAY is more volatile compared to GMED. This indicates higher risk in terms of short-term price fluctuations for BWAY.Check GMED's competition here
Glaukos Corporation (NYSE: GKOS)
BWAY vs GKOS Comparison August 2026
BrainsWay Ltd. (NASDAQ: BWAY) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BWAY stands at 587.6M. In comparison, GKOS has a market cap of 10.7B. Regarding current trading prices, BWAY is priced at $14.98 on the NASDAQ, while GKOS trades at $182.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BWAY currently has a P/E ratio of 38.06, whereas GKOS's P/E ratio is -211.72. In terms of profitability, BWAY's ROE is +0.12%, compared to GKOS's ROE of -0.27%. Regarding short-term risk, BWAY is less volatile compared to GKOS. This indicates lower risk in terms of short-term price fluctuations for BWAY.Check GKOS's competition here
Insulet Corp. (NASDAQ: PODD)
BWAY vs PODD Comparison August 2026
BrainsWay Ltd. (NASDAQ: BWAY) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BWAY stands at 587.6M. In comparison, PODD has a market cap of 10B. Regarding current trading prices, BWAY is priced at $14.98 on the NASDAQ, while PODD trades at $144.70.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BWAY currently has a P/E ratio of 38.06, whereas PODD's P/E ratio is 24.65. In terms of profitability, BWAY's ROE is +0.12%, compared to PODD's ROE of +0.27%. Regarding short-term risk, BWAY is less volatile compared to PODD. This indicates lower risk in terms of short-term price fluctuations for BWAY.Check PODD's competition here
Bio-Rad Laboratories, Inc. (NYSE: BIO)
BWAY vs BIO Comparison August 2026
BrainsWay Ltd. (NASDAQ: BWAY) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BWAY stands at 587.6M. In comparison, BIO has a market cap of 9.6B. Regarding current trading prices, BWAY is priced at $14.98 on the NASDAQ, while BIO trades at $356.25.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BWAY currently has a P/E ratio of 38.06, whereas BIO's P/E ratio is 38.40. In terms of profitability, BWAY's ROE is +0.12%, compared to BIO's ROE of +0.03%. Regarding short-term risk, BWAY is more volatile compared to BIO. This indicates higher risk in terms of short-term price fluctuations for BWAY.Check BIO's competition here
Bio-Rad Laboratories, Inc. (NYSE: BIO-B)
BWAY vs BIO-B Comparison August 2026
BrainsWay Ltd. (NASDAQ: BWAY) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BWAY stands at 587.6M. In comparison, BIO-B has a market cap of 9.5B. Regarding current trading prices, BWAY is priced at $14.98 on the NASDAQ, while BIO-B trades at $348.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BWAY currently has a P/E ratio of 38.06, whereas BIO-B's P/E ratio is 103.33. In terms of profitability, BWAY's ROE is +0.12%, compared to BIO-B's ROE of +0.03%. Regarding short-term risk, BWAY is more volatile compared to BIO-B. This indicates higher risk in terms of short-term price fluctuations for BWAY.Check BIO-B's competition here
Masimo Corporation (NASDAQ: MASI)
BWAY vs MASI Comparison August 2026
BrainsWay Ltd. (NASDAQ: BWAY) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BWAY stands at 587.6M. In comparison, MASI has a market cap of 9.4B. Regarding current trading prices, BWAY is priced at $14.98 on the NASDAQ, while MASI trades at $179.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BWAY currently has a P/E ratio of 38.06, whereas MASI's P/E ratio is 44.43. In terms of profitability, BWAY's ROE is +0.12%, compared to MASI's ROE of +0.09%. Regarding short-term risk, BWAY is more volatile compared to MASI. This indicates higher risk in terms of short-term price fluctuations for BWAY.Check MASI's competition here
Bruker Corporation (NASDAQ: BRKR)
BWAY vs BRKR Comparison August 2026
BrainsWay Ltd. (NASDAQ: BWAY) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BWAY stands at 587.6M. In comparison, BRKR has a market cap of 8.7B. Regarding current trading prices, BWAY is priced at $14.98 on the NASDAQ, while BRKR trades at $57.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BWAY currently has a P/E ratio of 38.06, whereas BRKR's P/E ratio is 28.65. In terms of profitability, BWAY's ROE is +0.12%, compared to BRKR's ROE of -0.03%. Regarding short-term risk, BWAY is less volatile compared to BRKR. This indicates lower risk in terms of short-term price fluctuations for BWAY.Check BRKR's competition here
Inari Medical, Inc. (NASDAQ: NARI)
BWAY vs NARI Comparison August 2026
BrainsWay Ltd. (NASDAQ: BWAY) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BWAY stands at 587.6M. In comparison, NARI has a market cap of 4.7B. Regarding current trading prices, BWAY is priced at $14.98 on the NASDAQ, while NARI trades at $79.97.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BWAY currently has a P/E ratio of 38.06, whereas NARI's P/E ratio is -59.24. In terms of profitability, BWAY's ROE is +0.12%, compared to NARI's ROE of -0.00%. Regarding short-term risk, BWAY is more volatile compared to NARI. This indicates higher risk in terms of short-term price fluctuations for BWAY.Check NARI's competition here
LivaNova PLC (NASDAQ: LIVN)
BWAY vs LIVN Comparison August 2026
BrainsWay Ltd. (NASDAQ: BWAY) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BWAY stands at 587.6M. In comparison, LIVN has a market cap of 4.3B. Regarding current trading prices, BWAY is priced at $14.98 on the NASDAQ, while LIVN trades at $78.58.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BWAY currently has a P/E ratio of 38.06, whereas LIVN's P/E ratio is 18.67. In terms of profitability, BWAY's ROE is +0.12%, compared to LIVN's ROE of +0.15%. Regarding short-term risk, BWAY is less volatile compared to LIVN. This indicates lower risk in terms of short-term price fluctuations for BWAY.Check LIVN's competition here
Integer Holdings Corporation (NYSE: ITGR)
BWAY vs ITGR Comparison August 2026
BrainsWay Ltd. (NASDAQ: BWAY) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BWAY stands at 587.6M. In comparison, ITGR has a market cap of 4.2B. Regarding current trading prices, BWAY is priced at $14.98 on the NASDAQ, while ITGR trades at $125.04.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BWAY currently has a P/E ratio of 38.06, whereas ITGR's P/E ratio is 19.69. In terms of profitability, BWAY's ROE is +0.12%, compared to ITGR's ROE of +0.07%. Regarding short-term risk, BWAY is more volatile compared to ITGR. This indicates higher risk in terms of short-term price fluctuations for BWAY.Check ITGR's competition here
iRhythm Technologies, Inc. (NASDAQ: IRTC)
BWAY vs IRTC Comparison August 2026
BrainsWay Ltd. (NASDAQ: BWAY) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BWAY stands at 587.6M. In comparison, IRTC has a market cap of 4B. Regarding current trading prices, BWAY is priced at $14.98 on the NASDAQ, while IRTC trades at $121.87.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BWAY currently has a P/E ratio of 38.06, whereas IRTC's P/E ratio is -190.42. In terms of profitability, BWAY's ROE is +0.12%, compared to IRTC's ROE of -0.09%. Regarding short-term risk, BWAY is less volatile compared to IRTC. This indicates lower risk in terms of short-term price fluctuations for BWAY.Check IRTC's competition here
Haemonetics Corporation (NYSE: HAE)
BWAY vs HAE Comparison August 2026
BrainsWay Ltd. (NASDAQ: BWAY) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BWAY stands at 587.6M. In comparison, HAE has a market cap of 4B. Regarding current trading prices, BWAY is priced at $14.98 on the NASDAQ, while HAE trades at $87.22.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BWAY currently has a P/E ratio of 38.06, whereas HAE's P/E ratio is 17.42. In terms of profitability, BWAY's ROE is +0.12%, compared to HAE's ROE of +0.11%. Regarding short-term risk, BWAY is less volatile compared to HAE. This indicates lower risk in terms of short-term price fluctuations for BWAY.Check HAE's competition here
Axonics, Inc. (NASDAQ: AXNX)
BWAY vs AXNX Comparison August 2026
BrainsWay Ltd. (NASDAQ: BWAY) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BWAY stands at 587.6M. In comparison, AXNX has a market cap of 3.6B. Regarding current trading prices, BWAY is priced at $14.98 on the NASDAQ, while AXNX trades at $70.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BWAY currently has a P/E ratio of 38.06, whereas AXNX's P/E ratio is -709.80. In terms of profitability, BWAY's ROE is +0.12%, compared to AXNX's ROE of -0.01%. Regarding short-term risk, BWAY is more volatile compared to AXNX. This indicates higher risk in terms of short-term price fluctuations for BWAY.Check AXNX's competition here
TransMedics Group, Inc. (NASDAQ: TMDX)
BWAY vs TMDX Comparison August 2026
BrainsWay Ltd. (NASDAQ: BWAY) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BWAY stands at 587.6M. In comparison, TMDX has a market cap of 3.1B. Regarding current trading prices, BWAY is priced at $14.98 on the NASDAQ, while TMDX trades at $89.36.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BWAY currently has a P/E ratio of 38.06, whereas TMDX's P/E ratio is 45.36. In terms of profitability, BWAY's ROE is +0.12%, compared to TMDX's ROE of +0.33%. Regarding short-term risk, BWAY is less volatile compared to TMDX. This indicates lower risk in terms of short-term price fluctuations for BWAY.Check TMDX's competition here
AxoGen, Inc. (NASDAQ: AXGN)
BWAY vs AXGN Comparison August 2026
BrainsWay Ltd. (NASDAQ: BWAY) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BWAY stands at 587.6M. In comparison, AXGN has a market cap of 2.6B. Regarding current trading prices, BWAY is priced at $14.98 on the NASDAQ, while AXGN trades at $48.48.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BWAY currently has a P/E ratio of 38.06, whereas AXGN's P/E ratio is 127.58. In terms of profitability, BWAY's ROE is +0.12%, compared to AXGN's ROE of -0.18%. Regarding short-term risk, BWAY is less volatile compared to AXGN. This indicates lower risk in terms of short-term price fluctuations for BWAY.Check AXGN's competition here
Butterfly Network, Inc. (NYSE: BFLY)
BWAY vs BFLY Comparison August 2026
BrainsWay Ltd. (NASDAQ: BWAY) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BWAY stands at 587.6M. In comparison, BFLY has a market cap of 2.5B. Regarding current trading prices, BWAY is priced at $14.98 on the NASDAQ, while BFLY trades at $9.37.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BWAY currently has a P/E ratio of 38.06, whereas BFLY's P/E ratio is -39.02. In terms of profitability, BWAY's ROE is +0.12%, compared to BFLY's ROE of -0.38%. Regarding short-term risk, BWAY is less volatile compared to BFLY. This indicates lower risk in terms of short-term price fluctuations for BWAY.Check BFLY's competition here
UFP Technologies, Inc. (NASDAQ: UFPT)
BWAY vs UFPT Comparison August 2026
BrainsWay Ltd. (NASDAQ: BWAY) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BWAY stands at 587.6M. In comparison, UFPT has a market cap of 2.5B. Regarding current trading prices, BWAY is priced at $14.98 on the NASDAQ, while UFPT trades at $321.91.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BWAY currently has a P/E ratio of 38.06, whereas UFPT's P/E ratio is 32.88. In terms of profitability, BWAY's ROE is +0.12%, compared to UFPT's ROE of +0.17%. Regarding short-term risk, BWAY is less volatile compared to UFPT. This indicates lower risk in terms of short-term price fluctuations for BWAY.Check UFPT's competition here
Establishment Labs Holdings Inc. (NASDAQ: ESTA)
BWAY vs ESTA Comparison August 2026
BrainsWay Ltd. (NASDAQ: BWAY) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BWAY stands at 587.6M. In comparison, ESTA has a market cap of 2.2B. Regarding current trading prices, BWAY is priced at $14.98 on the NASDAQ, while ESTA trades at $74.28.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BWAY currently has a P/E ratio of 38.06, whereas ESTA's P/E ratio is -58.95. In terms of profitability, BWAY's ROE is +0.12%, compared to ESTA's ROE of -2.04%. Regarding short-term risk, BWAY is less volatile compared to ESTA. This indicates lower risk in terms of short-term price fluctuations for BWAY.Check ESTA's competition here
NuVasive, Inc. (NASDAQ: NUVA)
BWAY vs NUVA Comparison August 2026
BrainsWay Ltd. (NASDAQ: BWAY) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BWAY stands at 587.6M. In comparison, NUVA has a market cap of 2.1B. Regarding current trading prices, BWAY is priced at $14.98 on the NASDAQ, while NUVA trades at $39.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BWAY currently has a P/E ratio of 38.06, whereas NUVA's P/E ratio is 75.00. In terms of profitability, BWAY's ROE is +0.12%, compared to NUVA's ROE of +0.05%. Regarding short-term risk, BWAY is less volatile compared to NUVA. This indicates lower risk in terms of short-term price fluctuations for BWAY.Check NUVA's competition here
Novocure Ltd (NASDAQ: NVCR)
BWAY vs NVCR Comparison August 2026
BrainsWay Ltd. (NASDAQ: BWAY) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BWAY stands at 587.6M. In comparison, NVCR has a market cap of 2.1B. Regarding current trading prices, BWAY is priced at $14.98 on the NASDAQ, while NVCR trades at $17.66.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BWAY currently has a P/E ratio of 38.06, whereas NVCR's P/E ratio is -11.54. In terms of profitability, BWAY's ROE is +0.12%, compared to NVCR's ROE of -0.44%. Regarding short-term risk, BWAY is less volatile compared to NVCR. This indicates lower risk in terms of short-term price fluctuations for BWAY.Check NVCR's competition here
Inspire Medical Systems, Inc. (NYSE: INSP)
BWAY vs INSP Comparison August 2026
BrainsWay Ltd. (NASDAQ: BWAY) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BWAY stands at 587.6M. In comparison, INSP has a market cap of 1.7B. Regarding current trading prices, BWAY is priced at $14.98 on the NASDAQ, while INSP trades at $59.13.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BWAY currently has a P/E ratio of 38.06, whereas INSP's P/E ratio is 26.07. In terms of profitability, BWAY's ROE is +0.12%, compared to INSP's ROE of +0.18%. Regarding short-term risk, BWAY is less volatile compared to INSP. This indicates lower risk in terms of short-term price fluctuations for BWAY.Check INSP's competition here
Tandem Diabetes Care, Inc. (NASDAQ: TNDM)
BWAY vs TNDM Comparison August 2026
BrainsWay Ltd. (NASDAQ: BWAY) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BWAY stands at 587.6M. In comparison, TNDM has a market cap of 1.6B. Regarding current trading prices, BWAY is priced at $14.98 on the NASDAQ, while TNDM trades at $23.44.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BWAY currently has a P/E ratio of 38.06, whereas TNDM's P/E ratio is -21.31. In terms of profitability, BWAY's ROE is +0.12%, compared to TNDM's ROE of -0.46%. Regarding short-term risk, BWAY is less volatile compared to TNDM. This indicates lower risk in terms of short-term price fluctuations for BWAY.Check TNDM's competition here
CONMED Corporation (NYSE: CNMD)
BWAY vs CNMD Comparison August 2026
BrainsWay Ltd. (NASDAQ: BWAY) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BWAY stands at 587.6M. In comparison, CNMD has a market cap of 1.5B. Regarding current trading prices, BWAY is priced at $14.98 on the NASDAQ, while CNMD trades at $49.58.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BWAY currently has a P/E ratio of 38.06, whereas CNMD's P/E ratio is 10.89. In terms of profitability, BWAY's ROE is +0.12%, compared to CNMD's ROE of +0.06%. Regarding short-term risk, BWAY is more volatile compared to CNMD. This indicates higher risk in terms of short-term price fluctuations for BWAY.Check CNMD's competition here
Alphatec Holdings, Inc. (NASDAQ: ATEC)
BWAY vs ATEC Comparison August 2026
BrainsWay Ltd. (NASDAQ: BWAY) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BWAY stands at 587.6M. In comparison, ATEC has a market cap of 1.4B. Regarding current trading prices, BWAY is priced at $14.98 on the NASDAQ, while ATEC trades at $9.37.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BWAY currently has a P/E ratio of 38.06, whereas ATEC's P/E ratio is -156.17. In terms of profitability, BWAY's ROE is +0.12%, compared to ATEC's ROE of -8.19%. Regarding short-term risk, BWAY is less volatile compared to ATEC. This indicates lower risk in terms of short-term price fluctuations for BWAY.Check ATEC's competition here
Enovis Corporation (NYSE: ENOV)
BWAY vs ENOV Comparison August 2026
BrainsWay Ltd. (NASDAQ: BWAY) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BWAY stands at 587.6M. In comparison, ENOV has a market cap of 1.4B. Regarding current trading prices, BWAY is priced at $14.98 on the NASDAQ, while ENOV trades at $24.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BWAY currently has a P/E ratio of 38.06, whereas ENOV's P/E ratio is 7.05. In terms of profitability, BWAY's ROE is +0.12%, compared to ENOV's ROE of -0.68%. Regarding short-term risk, BWAY is less volatile compared to ENOV. This indicates lower risk in terms of short-term price fluctuations for BWAY.Check ENOV's competition here
Artivion, Inc. (NYSE: AORT)
BWAY vs AORT Comparison August 2026
BrainsWay Ltd. (NASDAQ: BWAY) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BWAY stands at 587.6M. In comparison, AORT has a market cap of 1.4B. Regarding current trading prices, BWAY is priced at $14.98 on the NASDAQ, while AORT trades at $28.39.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BWAY currently has a P/E ratio of 38.06, whereas AORT's P/E ratio is 47.35. In terms of profitability, BWAY's ROE is +0.12%, compared to AORT's ROE of -0.01%. Regarding short-term risk, BWAY is less volatile compared to AORT. This indicates lower risk in terms of short-term price fluctuations for BWAY.Check AORT's competition here
Integra LifeSciences Holdings Corporation (NASDAQ: IART)
BWAY vs IART Comparison August 2026
BrainsWay Ltd. (NASDAQ: BWAY) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BWAY stands at 587.6M. In comparison, IART has a market cap of 1.4B. Regarding current trading prices, BWAY is priced at $14.98 on the NASDAQ, while IART trades at $17.37.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BWAY currently has a P/E ratio of 38.06, whereas IART's P/E ratio is 7.36. In terms of profitability, BWAY's ROE is +0.12%, compared to IART's ROE of -0.01%. Regarding short-term risk, BWAY is less volatile compared to IART. This indicates lower risk in terms of short-term price fluctuations for BWAY.Check IART's competition here
Heska Corporation (NASDAQ: HSKA)
BWAY vs HSKA Comparison August 2026
BrainsWay Ltd. (NASDAQ: BWAY) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BWAY stands at 587.6M. In comparison, HSKA has a market cap of 1.3B. Regarding current trading prices, BWAY is priced at $14.98 on the NASDAQ, while HSKA trades at $119.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BWAY currently has a P/E ratio of 38.06, whereas HSKA's P/E ratio is -62.49. In terms of profitability, BWAY's ROE is +0.12%, compared to HSKA's ROE of -0.04%. Regarding short-term risk, BWAY is more volatile compared to HSKA. This indicates higher risk in terms of short-term price fluctuations for BWAY.Check HSKA's competition here
PROCEPT BioRobotics Corporation (NASDAQ: PRCT)
BWAY vs PRCT Comparison August 2026
BrainsWay Ltd. (NASDAQ: BWAY) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BWAY stands at 587.6M. In comparison, PRCT has a market cap of 1.3B. Regarding current trading prices, BWAY is priced at $14.98 on the NASDAQ, while PRCT trades at $22.89.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BWAY currently has a P/E ratio of 38.06, whereas PRCT's P/E ratio is -11.80. In terms of profitability, BWAY's ROE is +0.12%, compared to PRCT's ROE of -0.31%. Regarding short-term risk, BWAY is less volatile compared to PRCT. This indicates lower risk in terms of short-term price fluctuations for BWAY.Check PRCT's competition here
Avanos Medical, Inc. (NYSE: AVNS)
BWAY vs AVNS Comparison August 2026
BrainsWay Ltd. (NASDAQ: BWAY) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BWAY stands at 587.6M. In comparison, AVNS has a market cap of 1.2B. Regarding current trading prices, BWAY is priced at $14.98 on the NASDAQ, while AVNS trades at $24.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BWAY currently has a P/E ratio of 38.06, whereas AVNS's P/E ratio is 27.77. In terms of profitability, BWAY's ROE is +0.12%, compared to AVNS's ROE of -0.09%. Regarding short-term risk, BWAY is more volatile compared to AVNS. This indicates higher risk in terms of short-term price fluctuations for BWAY.Check AVNS's competition here
IRadimed Corporation (NASDAQ: IRMD)
BWAY vs IRMD Comparison August 2026
BrainsWay Ltd. (NASDAQ: BWAY) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BWAY stands at 587.6M. In comparison, IRMD has a market cap of 1.1B. Regarding current trading prices, BWAY is priced at $14.98 on the NASDAQ, while IRMD trades at $88.94.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BWAY currently has a P/E ratio of 38.06, whereas IRMD's P/E ratio is 44.69. In terms of profitability, BWAY's ROE is +0.12%, compared to IRMD's ROE of +0.23%. Regarding short-term risk, BWAY is less volatile compared to IRMD. This indicates lower risk in terms of short-term price fluctuations for BWAY.Check IRMD's competition here
Lumexa Imaging Holdings, Inc. Common Stock (NASDAQ: LMRI)
BWAY vs LMRI Comparison August 2026
BrainsWay Ltd. (NASDAQ: BWAY) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BWAY stands at 587.6M. In comparison, LMRI has a market cap of 1.1B. Regarding current trading prices, BWAY is priced at $14.98 on the NASDAQ, while LMRI trades at $11.66.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BWAY currently has a P/E ratio of 38.06, whereas LMRI's P/E ratio is -22.69. In terms of profitability, BWAY's ROE is +0.12%, compared to LMRI's ROE of -0.06%. Regarding short-term risk, BWAY is less volatile compared to LMRI. This indicates lower risk in terms of short-term price fluctuations for BWAY.Check LMRI's competition here
Silk Road Medical, Inc (NASDAQ: SILK)
BWAY vs SILK Comparison August 2026
BrainsWay Ltd. (NASDAQ: BWAY) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BWAY stands at 587.6M. In comparison, SILK has a market cap of 1.1B. Regarding current trading prices, BWAY is priced at $14.98 on the NASDAQ, while SILK trades at $27.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BWAY currently has a P/E ratio of 38.06, whereas SILK's P/E ratio is -18.96. In terms of profitability, BWAY's ROE is +0.12%, compared to SILK's ROE of -0.35%. Regarding short-term risk, BWAY is more volatile compared to SILK. This indicates higher risk in terms of short-term price fluctuations for BWAY.Check SILK's competition here
Paragon 28, Inc. (NYSE: FNA)
BWAY vs FNA Comparison August 2026
BrainsWay Ltd. (NASDAQ: BWAY) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BWAY stands at 587.6M. In comparison, FNA has a market cap of 1.1B. Regarding current trading prices, BWAY is priced at $14.98 on the NASDAQ, while FNA trades at $13.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BWAY currently has a P/E ratio of 38.06, whereas FNA's P/E ratio is -19.83. In terms of profitability, BWAY's ROE is +0.12%, compared to FNA's ROE of -0.35%. Regarding short-term risk, BWAY is more volatile compared to FNA. This indicates higher risk in terms of short-term price fluctuations for BWAY.Check FNA's competition here
Bioventus Inc. (NASDAQ: BVS)
BWAY vs BVS Comparison August 2026
BrainsWay Ltd. (NASDAQ: BWAY) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BWAY stands at 587.6M. In comparison, BVS has a market cap of 938.3M. Regarding current trading prices, BWAY is priced at $14.98 on the NASDAQ, while BVS trades at $13.85.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BWAY currently has a P/E ratio of 38.06, whereas BVS's P/E ratio is 18.22. In terms of profitability, BWAY's ROE is +0.12%, compared to BVS's ROE of +0.28%. Regarding short-term risk, BWAY is more volatile compared to BVS. This indicates higher risk in terms of short-term price fluctuations for BWAY.Check BVS's competition here
Anteris Technologies Global Corp. (NASDAQ: AVR)
BWAY vs AVR Comparison August 2026
BrainsWay Ltd. (NASDAQ: BWAY) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BWAY stands at 587.6M. In comparison, AVR has a market cap of 891.6M. Regarding current trading prices, BWAY is priced at $14.98 on the NASDAQ, while AVR trades at $9.17.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BWAY currently has a P/E ratio of 38.06, whereas AVR's P/E ratio is -4.11. In terms of profitability, BWAY's ROE is +0.12%, compared to AVR's ROE of -1.24%. Regarding short-term risk, BWAY is less volatile compared to AVR. This indicates lower risk in terms of short-term price fluctuations for BWAY.Check AVR's competition here
InMode Ltd. (NASDAQ: INMD)
BWAY vs INMD Comparison August 2026
BrainsWay Ltd. (NASDAQ: BWAY) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BWAY stands at 587.6M. In comparison, INMD has a market cap of 870.3M. Regarding current trading prices, BWAY is priced at $14.98 on the NASDAQ, while INMD trades at $15.14.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BWAY currently has a P/E ratio of 38.06, whereas INMD's P/E ratio is 10.51. In terms of profitability, BWAY's ROE is +0.12%, compared to INMD's ROE of +0.12%. Regarding short-term risk, BWAY is more volatile compared to INMD. This indicates higher risk in terms of short-term price fluctuations for BWAY.Check INMD's competition here
Cardiovascular Systems, Inc. (NASDAQ: CSII)
BWAY vs CSII Comparison August 2026
BrainsWay Ltd. (NASDAQ: BWAY) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BWAY stands at 587.6M. In comparison, CSII has a market cap of 844M. Regarding current trading prices, BWAY is priced at $14.98 on the NASDAQ, while CSII trades at $20.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BWAY currently has a P/E ratio of 38.06, whereas CSII's P/E ratio is -20.83. In terms of profitability, BWAY's ROE is +0.12%, compared to CSII's ROE of -0.14%. Regarding short-term risk, BWAY is more volatile compared to CSII. This indicates higher risk in terms of short-term price fluctuations for BWAY.Check CSII's competition here
SI-BONE, Inc. (NASDAQ: SIBN)
BWAY vs SIBN Comparison August 2026
BrainsWay Ltd. (NASDAQ: BWAY) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BWAY stands at 587.6M. In comparison, SIBN has a market cap of 833.8M. Regarding current trading prices, BWAY is priced at $14.98 on the NASDAQ, while SIBN trades at $18.80.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BWAY currently has a P/E ratio of 38.06, whereas SIBN's P/E ratio is -55.29. In terms of profitability, BWAY's ROE is +0.12%, compared to SIBN's ROE of -0.08%. Regarding short-term risk, BWAY is less volatile compared to SIBN. This indicates lower risk in terms of short-term price fluctuations for BWAY.Check SIBN's competition here
CeriBell, Inc. (NASDAQ: CBLL)
BWAY vs CBLL Comparison August 2026
BrainsWay Ltd. (NASDAQ: BWAY) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BWAY stands at 587.6M. In comparison, CBLL has a market cap of 808.6M. Regarding current trading prices, BWAY is priced at $14.98 on the NASDAQ, while CBLL trades at $21.31.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BWAY currently has a P/E ratio of 38.06, whereas CBLL's P/E ratio is -13.07. In terms of profitability, BWAY's ROE is +0.12%, compared to CBLL's ROE of -0.45%. Regarding short-term risk, BWAY is less volatile compared to CBLL. This indicates lower risk in terms of short-term price fluctuations for BWAY.Check CBLL's competition here
Beta Bionics, Inc. (NASDAQ: BBNX)
BWAY vs BBNX Comparison August 2026
BrainsWay Ltd. (NASDAQ: BWAY) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BWAY stands at 587.6M. In comparison, BBNX has a market cap of 792.7M. Regarding current trading prices, BWAY is priced at $14.98 on the NASDAQ, while BBNX trades at $17.62.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BWAY currently has a P/E ratio of 38.06, whereas BBNX's P/E ratio is -11.67. In terms of profitability, BWAY's ROE is +0.12%, compared to BBNX's ROE of -0.26%. Regarding short-term risk, BWAY is less volatile compared to BBNX. This indicates lower risk in terms of short-term price fluctuations for BWAY.Check BBNX's competition here
Varex Imaging Corporation (NASDAQ: VREX)
BWAY vs VREX Comparison August 2026
BrainsWay Ltd. (NASDAQ: BWAY) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BWAY stands at 587.6M. In comparison, VREX has a market cap of 782.2M. Regarding current trading prices, BWAY is priced at $14.98 on the NASDAQ, while VREX trades at $18.58.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BWAY currently has a P/E ratio of 38.06, whereas VREX's P/E ratio is 19.56. In terms of profitability, BWAY's ROE is +0.12%, compared to VREX's ROE of +0.05%. Regarding short-term risk, BWAY is more volatile compared to VREX. This indicates higher risk in terms of short-term price fluctuations for BWAY.Check VREX's competition here
AdaptHealth Corp. (NASDAQ: AHCO)
BWAY vs AHCO Comparison August 2026
BrainsWay Ltd. (NASDAQ: BWAY) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BWAY stands at 587.6M. In comparison, AHCO has a market cap of 768.7M. Regarding current trading prices, BWAY is priced at $14.98 on the NASDAQ, while AHCO trades at $5.65.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BWAY currently has a P/E ratio of 38.06, whereas AHCO's P/E ratio is 11.53. In terms of profitability, BWAY's ROE is +0.12%, compared to AHCO's ROE of -0.15%. Regarding short-term risk, BWAY is less volatile compared to AHCO. This indicates lower risk in terms of short-term price fluctuations for BWAY.Check AHCO's competition here
SS Innovations International, Inc. (NASDAQ: SSII)
BWAY vs SSII Comparison August 2026
BrainsWay Ltd. (NASDAQ: BWAY) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BWAY stands at 587.6M. In comparison, SSII has a market cap of 722.5M. Regarding current trading prices, BWAY is priced at $14.98 on the NASDAQ, while SSII trades at $3.61.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BWAY currently has a P/E ratio of 38.06, whereas SSII's P/E ratio is -70.41. In terms of profitability, BWAY's ROE is +0.12%, compared to SSII's ROE of -0.23%. Regarding short-term risk, BWAY is less volatile compared to SSII. This indicates lower risk in terms of short-term price fluctuations for BWAY.Check SSII's competition here
OrthoPediatrics Corp. (NASDAQ: KIDS)
BWAY vs KIDS Comparison August 2026
BrainsWay Ltd. (NASDAQ: BWAY) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BWAY stands at 587.6M. In comparison, KIDS has a market cap of 622.6M. Regarding current trading prices, BWAY is priced at $14.98 on the NASDAQ, while KIDS trades at $24.24.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BWAY currently has a P/E ratio of 38.06, whereas KIDS's P/E ratio is -20.54. In terms of profitability, BWAY's ROE is +0.12%, compared to KIDS's ROE of -0.12%. Regarding short-term risk, BWAY is less volatile compared to KIDS. This indicates lower risk in terms of short-term price fluctuations for BWAY.Check KIDS's competition here
Surmodics, Inc. (NASDAQ: SRDX)
BWAY vs SRDX Comparison August 2026
BrainsWay Ltd. (NASDAQ: BWAY) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BWAY stands at 587.6M. In comparison, SRDX has a market cap of 614.5M. Regarding current trading prices, BWAY is priced at $14.98 on the NASDAQ, while SRDX trades at $42.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BWAY currently has a P/E ratio of 38.06, whereas SRDX's P/E ratio is -34.66. In terms of profitability, BWAY's ROE is +0.12%, compared to SRDX's ROE of -0.10%. Regarding short-term risk, BWAY is more volatile compared to SRDX. This indicates higher risk in terms of short-term price fluctuations for BWAY.Check SRDX's competition here
Cytek Biosciences, Inc. (NASDAQ: CTKB)
BWAY vs CTKB Comparison August 2026
BrainsWay Ltd. (NASDAQ: BWAY) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BWAY stands at 587.6M. In comparison, CTKB has a market cap of 612.1M. Regarding current trading prices, BWAY is priced at $14.98 on the NASDAQ, while CTKB trades at $4.74.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BWAY currently has a P/E ratio of 38.06, whereas CTKB's P/E ratio is -25.11. In terms of profitability, BWAY's ROE is +0.12%, compared to CTKB's ROE of -0.24%. Regarding short-term risk, BWAY is less volatile compared to CTKB. This indicates lower risk in terms of short-term price fluctuations for BWAY.Check CTKB's competition here
Delcath Systems, Inc. (NASDAQ: DCTH)
BWAY vs DCTH Comparison August 2026
BrainsWay Ltd. (NASDAQ: BWAY) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BWAY stands at 587.6M. In comparison, DCTH has a market cap of 594.5M. Regarding current trading prices, BWAY is priced at $14.98 on the NASDAQ, while DCTH trades at $17.22.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BWAY currently has a P/E ratio of 38.06, whereas DCTH's P/E ratio is 1722.00. In terms of profitability, BWAY's ROE is +0.12%, compared to DCTH's ROE of +0.00%. Regarding short-term risk, BWAY is less volatile compared to DCTH. This indicates lower risk in terms of short-term price fluctuations for BWAY.Check DCTH's competition here
Apollo Endosurgery, Inc. (NASDAQ: APEN)
BWAY vs APEN Comparison August 2026
BrainsWay Ltd. (NASDAQ: BWAY) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BWAY stands at 587.6M. In comparison, APEN has a market cap of 579.7M. Regarding current trading prices, BWAY is priced at $14.98 on the NASDAQ, while APEN trades at $10.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BWAY currently has a P/E ratio of 38.06, whereas APEN's P/E ratio is -9.43. In terms of profitability, BWAY's ROE is +0.12%, compared to APEN's ROE of -0.85%. Regarding short-term risk, BWAY is more volatile compared to APEN. This indicates higher risk in terms of short-term price fluctuations for BWAY.Check APEN's competition here
Tactile Systems Technology, Inc. (NASDAQ: TCMD)
BWAY vs TCMD Comparison August 2026
BrainsWay Ltd. (NASDAQ: BWAY) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BWAY stands at 587.6M. In comparison, TCMD has a market cap of 544.7M. Regarding current trading prices, BWAY is priced at $14.98 on the NASDAQ, while TCMD trades at $24.15.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BWAY currently has a P/E ratio of 38.06, whereas TCMD's P/E ratio is 27.44. In terms of profitability, BWAY's ROE is +0.12%, compared to TCMD's ROE of +0.11%. Regarding short-term risk, BWAY is less volatile compared to TCMD. This indicates lower risk in terms of short-term price fluctuations for BWAY.Check TCMD's competition here
ZimVie Inc. (NASDAQ: ZIMV)
BWAY vs ZIMV Comparison August 2026
BrainsWay Ltd. (NASDAQ: BWAY) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BWAY stands at 587.6M. In comparison, ZIMV has a market cap of 535.6M. Regarding current trading prices, BWAY is priced at $14.98 on the NASDAQ, while ZIMV trades at $18.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BWAY currently has a P/E ratio of 38.06, whereas ZIMV's P/E ratio is -27.52. In terms of profitability, BWAY's ROE is +0.12%, compared to ZIMV's ROE of -0.01%. Regarding short-term risk, BWAY is more volatile compared to ZIMV. This indicates higher risk in terms of short-term price fluctuations for BWAY.Check ZIMV's competition here
Cerus Corporation (NASDAQ: CERS)
BWAY vs CERS Comparison August 2026
BrainsWay Ltd. (NASDAQ: BWAY) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BWAY stands at 587.6M. In comparison, CERS has a market cap of 516.9M. Regarding current trading prices, BWAY is priced at $14.98 on the NASDAQ, while CERS trades at $2.57.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BWAY currently has a P/E ratio of 38.06, whereas CERS's P/E ratio is -51.20. In terms of profitability, BWAY's ROE is +0.12%, compared to CERS's ROE of -0.10%. Regarding short-term risk, BWAY is less volatile compared to CERS. This indicates lower risk in terms of short-term price fluctuations for BWAY.Check CERS's competition here
NeuroPace, Inc. (NASDAQ: NPCE)
BWAY vs NPCE Comparison August 2026
BrainsWay Ltd. (NASDAQ: BWAY) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BWAY stands at 587.6M. In comparison, NPCE has a market cap of 512.4M. Regarding current trading prices, BWAY is priced at $14.98 on the NASDAQ, while NPCE trades at $15.05.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BWAY currently has a P/E ratio of 38.06, whereas NPCE's P/E ratio is -23.12. In terms of profitability, BWAY's ROE is +0.12%, compared to NPCE's ROE of -1.21%. Regarding short-term risk, BWAY is less volatile compared to NPCE. This indicates lower risk in terms of short-term price fluctuations for BWAY.Check NPCE's competition here
ClearPoint Neuro, Inc. (NASDAQ: CLPT)
BWAY vs CLPT Comparison August 2026
BrainsWay Ltd. (NASDAQ: BWAY) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BWAY stands at 587.6M. In comparison, CLPT has a market cap of 446.8M. Regarding current trading prices, BWAY is priced at $14.98 on the NASDAQ, while CLPT trades at $14.90.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BWAY currently has a P/E ratio of 38.06, whereas CLPT's P/E ratio is -12.63. In terms of profitability, BWAY's ROE is +0.12%, compared to CLPT's ROE of -1.88%. Regarding short-term risk, BWAY is less volatile compared to CLPT. This indicates lower risk in terms of short-term price fluctuations for BWAY.Check CLPT's competition here
Sight Sciences, Inc. (NASDAQ: SGHT)
BWAY vs SGHT Comparison August 2026
BrainsWay Ltd. (NASDAQ: BWAY) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BWAY stands at 587.6M. In comparison, SGHT has a market cap of 421.7M. Regarding current trading prices, BWAY is priced at $14.98 on the NASDAQ, while SGHT trades at $7.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BWAY currently has a P/E ratio of 38.06, whereas SGHT's P/E ratio is -13.84. In terms of profitability, BWAY's ROE is +0.12%, compared to SGHT's ROE of -0.51%. Regarding short-term risk, BWAY is less volatile compared to SGHT. This indicates lower risk in terms of short-term price fluctuations for BWAY.Check SGHT's competition here
Orthofix Medical Inc. (NASDAQ: OFIX)
BWAY vs OFIX Comparison August 2026
BrainsWay Ltd. (NASDAQ: BWAY) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BWAY stands at 587.6M. In comparison, OFIX has a market cap of 417.2M. Regarding current trading prices, BWAY is priced at $14.98 on the NASDAQ, while OFIX trades at $10.32.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BWAY currently has a P/E ratio of 38.06, whereas OFIX's P/E ratio is -13.48. In terms of profitability, BWAY's ROE is +0.12%, compared to OFIX's ROE of -0.14%. Regarding short-term risk, BWAY is less volatile compared to OFIX. This indicates lower risk in terms of short-term price fluctuations for BWAY.Check OFIX's competition here
Carlsmed, Inc. (NASDAQ: CARL)
BWAY vs CARL Comparison August 2026
BrainsWay Ltd. (NASDAQ: BWAY) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BWAY stands at 587.6M. In comparison, CARL has a market cap of 373.2M. Regarding current trading prices, BWAY is priced at $14.98 on the NASDAQ, while CARL trades at $13.73.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BWAY currently has a P/E ratio of 38.06, whereas CARL's P/E ratio is -9.60. In terms of profitability, BWAY's ROE is +0.12%, compared to CARL's ROE of -0.38%. Regarding short-term risk, BWAY is less volatile compared to CARL. This indicates lower risk in terms of short-term price fluctuations for BWAY.Check CARL's competition here
Picard Medical, Inc. (AMEX: PMI)
BWAY vs PMI Comparison August 2026
BrainsWay Ltd. (NASDAQ: BWAY) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BWAY stands at 587.6M. In comparison, PMI has a market cap of 368.7M. Regarding current trading prices, BWAY is priced at $14.98 on the NASDAQ, while PMI trades at $3.63.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BWAY currently has a P/E ratio of 38.06, whereas PMI's P/E ratio is -2.99. In terms of profitability, BWAY's ROE is +0.12%, compared to PMI's ROE of +4.99%. Regarding short-term risk, BWAY is less volatile compared to PMI. This indicates lower risk in terms of short-term price fluctuations for BWAY.Check PMI's competition here
Perspective Therapeutics, Inc. (AMEX: CATX)
BWAY vs CATX Comparison August 2026
BrainsWay Ltd. (NASDAQ: BWAY) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BWAY stands at 587.6M. In comparison, CATX has a market cap of 362.1M. Regarding current trading prices, BWAY is priced at $14.98 on the NASDAQ, while CATX trades at $3.18.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BWAY currently has a P/E ratio of 38.06, whereas CATX's P/E ratio is -2.25. In terms of profitability, BWAY's ROE is +0.12%, compared to CATX's ROE of -0.42%. Regarding short-term risk, BWAY is less volatile compared to CATX. This indicates lower risk in terms of short-term price fluctuations for BWAY.Check CATX's competition here
Pacific Biosciences of California, Inc. (NASDAQ: PACB)
BWAY vs PACB Comparison August 2026
BrainsWay Ltd. (NASDAQ: BWAY) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BWAY stands at 587.6M. In comparison, PACB has a market cap of 354.1M. Regarding current trading prices, BWAY is priced at $14.98 on the NASDAQ, while PACB trades at $1.14.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BWAY currently has a P/E ratio of 38.06, whereas PACB's P/E ratio is -2.78. In terms of profitability, BWAY's ROE is +0.12%, compared to PACB's ROE of -49.62%. Regarding short-term risk, BWAY is more volatile compared to PACB. This indicates higher risk in terms of short-term price fluctuations for BWAY.Check PACB's competition here
TriSalus Life Sciences, Inc. (NASDAQ: TLSI)
BWAY vs TLSI Comparison August 2026
BrainsWay Ltd. (NASDAQ: BWAY) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BWAY stands at 587.6M. In comparison, TLSI has a market cap of 353.4M. Regarding current trading prices, BWAY is priced at $14.98 on the NASDAQ, while TLSI trades at $5.74.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BWAY currently has a P/E ratio of 38.06, whereas TLSI's P/E ratio is -3.42. In terms of profitability, BWAY's ROE is +0.12%, compared to TLSI's ROE of +2.74%. Regarding short-term risk, BWAY is less volatile compared to TLSI. This indicates lower risk in terms of short-term price fluctuations for BWAY.Check TLSI's competition here
Electromed, Inc. (AMEX: ELMD)
BWAY vs ELMD Comparison August 2026
BrainsWay Ltd. (NASDAQ: BWAY) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BWAY stands at 587.6M. In comparison, ELMD has a market cap of 350.8M. Regarding current trading prices, BWAY is priced at $14.98 on the NASDAQ, while ELMD trades at $42.39.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BWAY currently has a P/E ratio of 38.06, whereas ELMD's P/E ratio is 36.21. In terms of profitability, BWAY's ROE is +0.12%, compared to ELMD's ROE of +0.22%. Regarding short-term risk, BWAY is less volatile compared to ELMD. This indicates lower risk in terms of short-term price fluctuations for BWAY.Check ELMD's competition here
CapsoVision, Inc. (NASDAQ: CV)
BWAY vs CV Comparison August 2026
BrainsWay Ltd. (NASDAQ: BWAY) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BWAY stands at 587.6M. In comparison, CV has a market cap of 329.8M. Regarding current trading prices, BWAY is priced at $14.98 on the NASDAQ, while CV trades at $6.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BWAY currently has a P/E ratio of 38.06, whereas CV's P/E ratio is -2.64. In terms of profitability, BWAY's ROE is +0.12%, compared to CV's ROE of +1.27%. Regarding short-term risk, BWAY is less volatile compared to CV. This indicates lower risk in terms of short-term price fluctuations for BWAY.Check CV's competition here
Senseonics Holdings, Inc. (NASDAQ: SENS)
BWAY vs SENS Comparison August 2026
BrainsWay Ltd. (NASDAQ: BWAY) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BWAY stands at 587.6M. In comparison, SENS has a market cap of 328.9M. Regarding current trading prices, BWAY is priced at $14.98 on the NASDAQ, while SENS trades at $7.87.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BWAY currently has a P/E ratio of 38.06, whereas SENS's P/E ratio is -3.93. In terms of profitability, BWAY's ROE is +0.12%, compared to SENS's ROE of -1.66%. Regarding short-term risk, BWAY is less volatile compared to SENS. This indicates lower risk in terms of short-term price fluctuations for BWAY.Check SENS's competition here
Semler Scientific, Inc. (NASDAQ: SMLR)
BWAY vs SMLR Comparison August 2026
BrainsWay Ltd. (NASDAQ: BWAY) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BWAY stands at 587.6M. In comparison, SMLR has a market cap of 310.7M. Regarding current trading prices, BWAY is priced at $14.98 on the NASDAQ, while SMLR trades at $20.33.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BWAY currently has a P/E ratio of 38.06, whereas SMLR's P/E ratio is 3.92. In terms of profitability, BWAY's ROE is +0.12%, compared to SMLR's ROE of +0.06%. Regarding short-term risk, BWAY is more volatile compared to SMLR. This indicates higher risk in terms of short-term price fluctuations for BWAY.Check SMLR's competition here
Treace Medical Concepts, Inc. (NASDAQ: TMCI)
BWAY vs TMCI Comparison August 2026
BrainsWay Ltd. (NASDAQ: BWAY) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BWAY stands at 587.6M. In comparison, TMCI has a market cap of 307.5M. Regarding current trading prices, BWAY is priced at $14.98 on the NASDAQ, while TMCI trades at $4.74.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BWAY currently has a P/E ratio of 38.06, whereas TMCI's P/E ratio is -5.04. In terms of profitability, BWAY's ROE is +0.12%, compared to TMCI's ROE of -0.74%. Regarding short-term risk, BWAY is less volatile compared to TMCI. This indicates lower risk in terms of short-term price fluctuations for BWAY.Check TMCI's competition here
RxSight, Inc. (NASDAQ: RXST)
BWAY vs RXST Comparison August 2026
BrainsWay Ltd. (NASDAQ: BWAY) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BWAY stands at 587.6M. In comparison, RXST has a market cap of 291.4M. Regarding current trading prices, BWAY is priced at $14.98 on the NASDAQ, while RXST trades at $7.04.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BWAY currently has a P/E ratio of 38.06, whereas RXST's P/E ratio is -7.57. In terms of profitability, BWAY's ROE is +0.12%, compared to RXST's ROE of -0.17%. Regarding short-term risk, BWAY is less volatile compared to RXST. This indicates lower risk in terms of short-term price fluctuations for BWAY.Check RXST's competition here
Anika Therapeutics, Inc. (NASDAQ: ANIK)
BWAY vs ANIK Comparison August 2026
BrainsWay Ltd. (NASDAQ: BWAY) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BWAY stands at 587.6M. In comparison, ANIK has a market cap of 284.1M. Regarding current trading prices, BWAY is priced at $14.98 on the NASDAQ, while ANIK trades at $21.23.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BWAY currently has a P/E ratio of 38.06, whereas ANIK's P/E ratio is 43.33. In terms of profitability, BWAY's ROE is +0.12%, compared to ANIK's ROE of -0.03%. Regarding short-term risk, BWAY is less volatile compared to ANIK. This indicates lower risk in terms of short-term price fluctuations for BWAY.Check ANIK's competition here
Profound Medical Corp. (NASDAQ: PROF)
BWAY vs PROF Comparison August 2026
BrainsWay Ltd. (NASDAQ: BWAY) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BWAY stands at 587.6M. In comparison, PROF has a market cap of 253.6M. Regarding current trading prices, BWAY is priced at $14.98 on the NASDAQ, while PROF trades at $6.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BWAY currently has a P/E ratio of 38.06, whereas PROF's P/E ratio is -5.63. In terms of profitability, BWAY's ROE is +0.12%, compared to PROF's ROE of -0.56%. Regarding short-term risk, BWAY is less volatile compared to PROF. This indicates lower risk in terms of short-term price fluctuations for BWAY.Check PROF's competition here
Monogram Orthopaedics, Inc. (NASDAQ: MGRM)
BWAY vs MGRM Comparison August 2026
BrainsWay Ltd. (NASDAQ: BWAY) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BWAY stands at 587.6M. In comparison, MGRM has a market cap of 243.8M. Regarding current trading prices, BWAY is priced at $14.98 on the NASDAQ, while MGRM trades at $6.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BWAY currently has a P/E ratio of 38.06, whereas MGRM's P/E ratio is -12.00. In terms of profitability, BWAY's ROE is +0.12%, compared to MGRM's ROE of -0.85%. Regarding short-term risk, BWAY is more volatile compared to MGRM. This indicates higher risk in terms of short-term price fluctuations for BWAY.Check MGRM's competition here
EDAP TMS S.A. American Depositary Shares (NASDAQ: FOCL)
BWAY vs FOCL Comparison August 2026
BrainsWay Ltd. (NASDAQ: BWAY) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BWAY stands at 587.6M. In comparison, FOCL has a market cap of 225.3M. Regarding current trading prices, BWAY is priced at $14.98 on the NASDAQ, while FOCL trades at $6.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BWAY currently has a P/E ratio of 38.06, whereas FOCL's P/E ratio is -7.33. In terms of profitability, BWAY's ROE is +0.12%, compared to FOCL's ROE of -1.38%. Regarding short-term risk, BWAY is less volatile compared to FOCL. This indicates lower risk in terms of short-term price fluctuations for BWAY.Check FOCL's competition here
Nevro Corp. (NYSE: NVRO)
BWAY vs NVRO Comparison August 2026
BrainsWay Ltd. (NASDAQ: BWAY) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BWAY stands at 587.6M. In comparison, NVRO has a market cap of 224.1M. Regarding current trading prices, BWAY is priced at $14.98 on the NASDAQ, while NVRO trades at $5.84.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BWAY currently has a P/E ratio of 38.06, whereas NVRO's P/E ratio is -1.91. In terms of profitability, BWAY's ROE is +0.12%, compared to NVRO's ROE of -0.43%. Regarding short-term risk, BWAY is more volatile compared to NVRO. This indicates higher risk in terms of short-term price fluctuations for BWAY.Check NVRO's competition here
Neuronetics, Inc. (NASDAQ: STIM)
BWAY vs STIM Comparison August 2026
BrainsWay Ltd. (NASDAQ: BWAY) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BWAY stands at 587.6M. In comparison, STIM has a market cap of 222M. Regarding current trading prices, BWAY is priced at $14.98 on the NASDAQ, while STIM trades at $3.19.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BWAY currently has a P/E ratio of 38.06, whereas STIM's P/E ratio is -5.91. In terms of profitability, BWAY's ROE is +0.12%, compared to STIM's ROE of -1.51%. Regarding short-term risk, BWAY is less volatile compared to STIM. This indicates lower risk in terms of short-term price fluctuations for BWAY.Check STIM's competition here
Avita Medical Inc. (NASDAQ: RCEL)
BWAY vs RCEL Comparison August 2026
BrainsWay Ltd. (NASDAQ: BWAY) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BWAY stands at 587.6M. In comparison, RCEL has a market cap of 203.7M. Regarding current trading prices, BWAY is priced at $14.98 on the NASDAQ, while RCEL trades at $8.20.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BWAY currently has a P/E ratio of 38.06, whereas RCEL's P/E ratio is -5.22. In terms of profitability, BWAY's ROE is +0.12%, compared to RCEL's ROE of +2.32%. Regarding short-term risk, BWAY is less volatile compared to RCEL. This indicates lower risk in terms of short-term price fluctuations for BWAY.Check RCEL's competition here
BioSig Technologies, Inc. (NASDAQ: BSGM)
BWAY vs BSGM Comparison August 2026
BrainsWay Ltd. (NASDAQ: BWAY) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BWAY stands at 587.6M. In comparison, BSGM has a market cap of 191.1M. Regarding current trading prices, BWAY is priced at $14.98 on the NASDAQ, while BSGM trades at $6.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BWAY currently has a P/E ratio of 38.06, whereas BSGM's P/E ratio is -5.81. In terms of profitability, BWAY's ROE is +0.12%, compared to BSGM's ROE of +15.26%. Regarding short-term risk, BWAY is less volatile compared to BSGM. This indicates lower risk in terms of short-term price fluctuations for BWAY.Check BSGM's competition here
Lucid Diagnostics Inc. (NASDAQ: LUCD)
BWAY vs LUCD Comparison August 2026
BrainsWay Ltd. (NASDAQ: BWAY) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BWAY stands at 587.6M. In comparison, LUCD has a market cap of 183.4M. Regarding current trading prices, BWAY is priced at $14.98 on the NASDAQ, while LUCD trades at $0.96.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BWAY currently has a P/E ratio of 38.06, whereas LUCD's P/E ratio is -2.60. In terms of profitability, BWAY's ROE is +0.12%, compared to LUCD's ROE of -3.70%. Regarding short-term risk, BWAY is less volatile compared to LUCD. This indicates lower risk in terms of short-term price fluctuations for BWAY.Check LUCD's competition here
Xylo Technologies Ltd. (NASDAQ: MDGS)
BWAY vs MDGS Comparison August 2026
BrainsWay Ltd. (NASDAQ: BWAY) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BWAY stands at 587.6M. In comparison, MDGS has a market cap of 178.9M. Regarding current trading prices, BWAY is priced at $14.98 on the NASDAQ, while MDGS trades at $2.36.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BWAY currently has a P/E ratio of 38.06, whereas MDGS's P/E ratio is -0.27. In terms of profitability, BWAY's ROE is +0.12%, compared to MDGS's ROE of -0.51%. Regarding short-term risk, BWAY is less volatile compared to MDGS. This indicates lower risk in terms of short-term price fluctuations for BWAY.Check MDGS's competition here
Quipt Home Medical Corp. (NASDAQ: QIPT)
BWAY vs QIPT Comparison August 2026
BrainsWay Ltd. (NASDAQ: BWAY) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BWAY stands at 587.6M. In comparison, QIPT has a market cap of 162.3M. Regarding current trading prices, BWAY is priced at $14.98 on the NASDAQ, while QIPT trades at $3.65.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BWAY currently has a P/E ratio of 38.06, whereas QIPT's P/E ratio is -15.87. In terms of profitability, BWAY's ROE is +0.12%, compared to QIPT's ROE of -0.10%. Regarding short-term risk, BWAY is more volatile compared to QIPT. This indicates higher risk in terms of short-term price fluctuations for BWAY.Check QIPT's competition here
Inogen, Inc. (NASDAQ: INGN)
BWAY vs INGN Comparison August 2026
BrainsWay Ltd. (NASDAQ: BWAY) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BWAY stands at 587.6M. In comparison, INGN has a market cap of 159.7M. Regarding current trading prices, BWAY is priced at $14.98 on the NASDAQ, while INGN trades at $5.90.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BWAY currently has a P/E ratio of 38.06, whereas INGN's P/E ratio is -6.48. In terms of profitability, BWAY's ROE is +0.12%, compared to INGN's ROE of -0.13%. Regarding short-term risk, BWAY is less volatile compared to INGN. This indicates lower risk in terms of short-term price fluctuations for BWAY.Check INGN's competition here
Quanterix Corporation (NASDAQ: QTRX)
BWAY vs QTRX Comparison August 2026
BrainsWay Ltd. (NASDAQ: BWAY) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BWAY stands at 587.6M. In comparison, QTRX has a market cap of 123.7M. Regarding current trading prices, BWAY is priced at $14.98 on the NASDAQ, while QTRX trades at $2.63.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BWAY currently has a P/E ratio of 38.06, whereas QTRX's P/E ratio is -1.64. In terms of profitability, BWAY's ROE is +0.12%, compared to QTRX's ROE of -0.44%. Regarding short-term risk, BWAY is less volatile compared to QTRX. This indicates lower risk in terms of short-term price fluctuations for BWAY.Check QTRX's competition here
iCAD, Inc. (NASDAQ: ICAD)
BWAY vs ICAD Comparison August 2026
BrainsWay Ltd. (NASDAQ: BWAY) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BWAY stands at 587.6M. In comparison, ICAD has a market cap of 106.3M. Regarding current trading prices, BWAY is priced at $14.98 on the NASDAQ, while ICAD trades at $3.87.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BWAY currently has a P/E ratio of 38.06, whereas ICAD's P/E ratio is -20.37. In terms of profitability, BWAY's ROE is +0.12%, compared to ICAD's ROE of -0.18%. Regarding short-term risk, BWAY is more volatile compared to ICAD. This indicates higher risk in terms of short-term price fluctuations for BWAY.Check ICAD's competition here
Solana Company (NASDAQ: HSDT)
BWAY vs HSDT Comparison August 2026
BrainsWay Ltd. (NASDAQ: BWAY) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BWAY stands at 587.6M. In comparison, HSDT has a market cap of 101.6M. Regarding current trading prices, BWAY is priced at $14.98 on the NASDAQ, while HSDT trades at $1.74.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BWAY currently has a P/E ratio of 38.06, whereas HSDT's P/E ratio is -0.02. In terms of profitability, BWAY's ROE is +0.12%, compared to HSDT's ROE of -1.55%. Regarding short-term risk, BWAY is less volatile compared to HSDT. This indicates lower risk in terms of short-term price fluctuations for BWAY.Check HSDT's competition here
Owlet, Inc. (NYSE: OWLT)
BWAY vs OWLT Comparison August 2026
BrainsWay Ltd. (NASDAQ: BWAY) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BWAY stands at 587.6M. In comparison, OWLT has a market cap of 98.4M. Regarding current trading prices, BWAY is priced at $14.98 on the NASDAQ, while OWLT trades at $5.44.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BWAY currently has a P/E ratio of 38.06, whereas OWLT's P/E ratio is -38.86. In terms of profitability, BWAY's ROE is +0.12%, compared to OWLT's ROE of +11.36%. Regarding short-term risk, BWAY is less volatile compared to OWLT. This indicates lower risk in terms of short-term price fluctuations for BWAY.Check OWLT's competition here
Hancock Jaffe Laboratories (NASDAQ: HJLI)
BWAY vs HJLI Comparison August 2026
BrainsWay Ltd. (NASDAQ: BWAY) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BWAY stands at 587.6M. In comparison, HJLI has a market cap of 98.3M. Regarding current trading prices, BWAY is priced at $14.98 on the NASDAQ, while HJLI trades at $10.38.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BWAY currently has a P/E ratio of 38.06, whereas HJLI's P/E ratio is N/A. In terms of profitability, BWAY's ROE is +0.12%, compared to HJLI's ROE of -0.62%. Regarding short-term risk, BWAY is less volatile compared to HJLI. This indicates lower risk in terms of short-term price fluctuations for BWAY.Check HJLI's competition here